ASTX030

A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Arms / Cohorts

Experimental:Phase 1, Stage A (Dose Escalation)

Accepting patients

Experimental:Phase 1, Stage B (Dose Expansion)

Accepting patients

Experimental:Phase 2, Sequence A

Accepting patients

Experimental:Phase 2, Sequence B

Accepting patients

Experimental:Phase 3, Sequence A

Accepting patients

Experimental:Phase 3, Sequence B

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.